Please assess the completion status of the following clinical trial:

Trial Title: Study of S-1 Plus LV for Advanced Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologically conﬁrmed metastatic or recurrent gastric cancer~* with at least one measurable lesion by RECIST criteria~* an age of ≥ 18~* adequate oral intake~* no previous radiotherapy, immunotherapy, biotherapy, hormonotherapy and chemotherapy within 5 years (adjuvant chemotherapy without S-1 was allowed if ﬁnished 6 months before enrollment)~* an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* adequate bone marrow function, hepatic function and renal functions~Exclusion Criteria:~* a history of hypersensitivity to S-1 or LV, usage of drugs interacting with S-1~* serious concomitant conditions (severe heart disease, pulmonary ﬁbrosis, intestinal obstruction, enteroplegia, renal failure, liver failure, pre-existing sensory neuropathy ≥ grade 2, uncontrolled infections, psychogenic disorders, human immunodeﬁciency virus infection, severe diarrhea, nausea, or vomiting, severe ascites or pleural effusion, etc.)~* extensive bone metastasis, brain metastasis or meningeal metastasis~* another synchronous cancer~* surgery within 3 weeks before enrollment~* participating in other clinical studies~* women who were or to be pregnant, nursing infants, and men who were to conceive children

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S-1 plus LV (Type: EXPERIMENTAL): All patients were orally treated with S-1 in doses of 40 mg (body surface area (BSA)\<1.25 m2), 50 mg (1.25≤BSA\<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-7 in combination with LV given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest. Treatment courses were repeated every 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).